REGENXBIO lines up Duchenne filing while MPS II trial stays frozen

REGENXBIO is steering its near-term plans towards Duchenne muscular dystrophy. Reporting third-quarter 2026 results on 5 November, the company said it aims to file a biologics licence application for RGX-202 in the first quarter of 2027 and will ask the US Food and Drug Administration for accelerated approval. A meeting with the agency to discuss the submission ahead of filing is scheduled for the final quarter of 2026.

The other programme with a near-term catalyst is in eye disease. Pivotal results are expected in the fourth quarter of 2026 for sura-vec, delivered under the retina in wet age-related macular degeneration. REGENXBIO is developing it with AbbVie. The company gave no further detail on the data or on what would follow.

Its therapy for mucopolysaccharidosis type II (MPS II, or Hunter syndrome), RGX-121, remains on clinical hold. The FDA imposed the hold in August after spine imaging flagged findings in five trial participants who had no symptoms. The material provided gave no date by which the hold might be lifted.

On the financial side, REGENXBIO posted a net loss of $40.7 million for the quarter. It expects its existing funds to last until late in the fourth quarter of 2027, a period that spans the planned Duchenne filing.

Context: accelerated approval generally rests on a surrogate or intermediate endpoint rather than final clinical outcomes, so the pre-filing discussion with the FDA will be the first sign of how the agency views the evidence.